PPTA Twitter

PlasmaProteins #TBT to PPTA’s interview with Val Bias, the former CEO of @NHF_Hemophilia to get a glimpse into the future for those living with #bleedingdisorders . Read more: bit.ly/2DZQ7Np pic.twitter.com/Fq9dRMJLLH
2 days ago.
PlasmaProteins “Ultimately, what drives my colleagues on the Board, my company, and the staff at PPTA is a focus on patients...” Karen Etchberger, of @CSLBehring , reflects on her election as Chair of @plasmaproteins Global Board of Directors. bit.ly/2u61VeZ pic.twitter.com/QKhDPwL1e0
9 days ago.

PPTA Responds to The Pharmaceutical Journal

In December 2017, The Pharmaceutical Journal published a correspondence piece that included a few misleading statements regarding the prospective use of gene therapy for treatment of common variable immune deficiency (CVID), when in reality, the treatment is only being discussed for a rare form of severe combined immunodeficiency caused by adenosine deaminase deficiency (SCID-ADA).

PPTA submitted a response to the original article with corrections to the original author's inaccuracies and misleading interpretations. The response article, "Keeping the record straight on the availability of gene therapy for common variable immunodeficiency," was published online last week.

plasma protein forum, , gene therapy, scid, cvid, pharmaceutical journal, immunodeficiency

Copyright © 2018 PPTA. All rights reserved. (202) 789-3100